Hancock Whitney’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$729K Sell
25,929
-7,019
-21% -$167K 0.01% 484
2025
Q4
$769K Buy
32,948
+292
+0.9% +$6.5K 0.01% 465
2025
Q3
$643K Sell
32,656
-5,629
-15% -$116K 0.01% 516
2025
Q2
$831K Sell
38,285
-562
-1% -$13.3K 0.02% 459
2025
Q1
$942K Buy
38,847
+525
+1% +$11.8K 0.03% 324
2024
Q4
$800K Sell
38,322
-606
-2% -$13K 0.03% 344
2024
Q3
$774K Sell
38,928
-1,928
-5% -$35.7K 0.02% 362
2024
Q2
$633K Buy
40,856
+88
+0.2% +$1.37K 0.02% 373
2024
Q1
$650K Buy
40,768
+12,361
+44% +$186K 0.02% 376
2023
Q4
$478K Sell
28,407
-470
-2% -$6.42K 0.02% 450
2023
Q3
$338K Sell
28,877
-65
-0.2% -$869 0.01% 501
2023
Q2
$388K Buy
28,942
+14,227
+97% +$205K 0.02% 478
2023
Q1
$244K Sell
14,715
-103
-0.7% -$1.7K 0.01% 578
2022
Q4
$275K Buy
+14,818
New +$228K 0.01% 550
2021
Q3
Sell
-238,281
Closed -$1.37M 696
2021
Q2
$1.37M Sell
238,281
-208
-0.1% -$1.07K 0.04% 353
2021
Q1
$1.1M Sell
238,489
-803
-0.3% -$3.19K 0.04% 390
2020
Q4
$799K Sell
239,292
-53,928
-18% -$181K 0.03% 426
2020
Q3
$871K Sell
293,220
-24,690
-8% -$96.5K 0.03% 396
2020
Q2
$1.47M Buy
+317,910
New +$1.43M 0.06% 295

Other funds holding CPRX

Hancock Whitney's CPRX Position: Q1 2026 in Review

Hancock Whitney reduced its Catalyst Pharmaceutical (CPRX) stake by 21% in Q1 2026, selling an estimated $167K and leaving 25,929 shares worth $729K. The position accounts for 0.01% of the portfolio, ranked #484.

Hancock Whitney first reported a position in CPRX in Q2 2020 and has held it in 19 quarters since. The position peaked at $1.47M in Q2 2020. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Hancock Whitney held 25,929 shares of Catalyst Pharmaceutical worth $729K as of Q1 2026.
  • Hancock Whitney sold 7,019 Catalyst Pharmaceutical shares in Q1 2026, an estimated $167K.
  • Catalyst Pharmaceutical made up 0.01% of Hancock Whitney's portfolio in Q1 2026, its #484 holding.
  • Hancock Whitney first reported a position in Catalyst Pharmaceutical in Q2 2020 and has held it in 19 quarters since.
  • Hancock Whitney's Catalyst Pharmaceutical position peaked at $1.47M in Q2 2020.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Hancock Whitney's 13F filing for Q1 2026, filed 15 May 2026.